Adeno associated viral vector (AAV) is the delivery vehicle of choice for potentially curative in vivo gene therapy. Following a couple of landmark approvals, this field has experienced accelerated pipeline growth and investor interest in the past years. Currently AAV therapies are predominantly targeting rare genetic disorders for which the patient population is often limited. As a result, drug developers feel immense pressure to be first to market to commercialize their therapies. In this Webinar, our expert discusses how to build reliable, de-risked path to clinic to avoid unforeseen costs and compliance-related delays.
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center